Visual Abstract

Background: There has been an increasing incidence of hemodialysis (HD) due to old age and comorbid condition such as diabetes. In general, socioeconomic status (SES) is known as one of the most important risk factors for patient mortality and morbidity. Whether low SES is associated with poorer outcome in HD patients is controversial. This study was performed to evaluate the association of health insurance status as a proxy indicator for SES upon mortality and hospitalization in maintenance HD patients. Methods: We used HD-quality assessment data from the year of 2015 for collecting demographic and clinical data. The subjects were classified into Medical Aid (MA) recipients (low SES) and National Health Insurance (NHI) beneficiary (high SES). We analyzed mortality and hospitalization risk based on health insurance status using Cox proportional hazard model. A total of 35,454 adult HD patients ≥18 years old who received HD treatment more than twice weekly were included in the analysis. Results: The ratio between MA recipient and NHI beneficiary was 76.7 versus 23.3%. The MA recipient group demonstrated younger age and lower proportion of female, diabetes, hypertension, and cerebrovascular accidents compared to the NHI beneficiary group. After adjusting for age, gender, comorbidity, and laboratory parameters, the MA recipient group showed a significantly higher mortality risk compared to the NHI beneficiary group (hazard ratio 1.073 [1.009–1.14], p = 0.025). The MA recipient group was also an independent risk factor for hospitalization after adjusting for age, gender, comorbidities, and laboratory parameters (hazard ratio 1.142 [1.108–1.178], p < 0.001). Conclusion: Low SES as measured by health insurance status was associated with an increased risk of patient mortality and hospitalization in Korean maintenance HD patients.

1.
Jin
DC
,
Yun
SR
,
Lee
SW
,
Han
SW
,
Kim
W
,
Park
J
.
Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients
.
Kidney Res Clin Pract
.
2016 Dec
;
35
(
4
):
204
11
. .
2.
Jin
DC
,
Yun
SR
,
Lee
SW
,
Han
SW
,
Kim
W
,
Park
J
, et al.
Current characteristics of dialysis therapy in Korea: 2016 registry data focusing on diabetic patients
.
Kidney Res Clin Pract
.
2018 Mar
;
37
(
1
):
20
9
. .
3.
ESRD Registry Committee KSoN
.
Current renal replacement therapy in Korea 2018
.
Seoul, Korea
:
Korean Society of Nephrology
;
2018
.
4.
Jin
DC
.
Analysis of mortality risk from Korean hemodialysis registry data 2017
.
Kidney Res Clin Pract
.
2019 Jun 30
;
38
(
2
):
169
75
. .
5.
Kimmel
PL
,
Fwu
CW
,
Eggers
PW
.
Segregation, income disparities, and survival in hemodialysis patients
.
J Am Soc Nephrol
.
2013 Feb
;
24
(
2
):
293
301
. .
6.
Johns
TS
,
Estrella
MM
,
Crews
DC
,
Appel
LJ
,
Anderson
CA
,
Ephraim
PL
, et al.
Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients
.
J Am Soc Nephrol
.
2014 Nov
;
25
(
11
):
2649
57
. .
7.
Krishnasamy
R
,
Gray
NA
.
Low socio-economic status adversely effects dialysis survival in Australia
.
Nephrology
.
2018 May
;
23
(
5
):
453
60
. .
8.
Caskey
FJ
,
Roderick
P
,
Steenkamp
R
,
Nitsch
D
,
Thomas
K
,
Ansell
D
, et al.
Social deprivation and survival on renal replacement therapy in England and Wales
.
Kidney Int
.
2006 Dec
;
70
(
12
):
2134
40
. .
9.
Eisenstein
EL
,
Sun
JL
,
Anstrom
KJ
,
Stafford
JA
,
Szczech
LA
,
Muhlbaier
LH
, et al.
Do income level and race influence survival in patients receiving hemodialysis?
Am J Med
.
2009 Feb
;
122
(
2
):
170
80
. .
10.
Hall
YN
.
Social determinants of health: addressing unmet needs in nephrology
.
Am J Kidney Dis
.
2018 Oct
;
72
(
4
):
582
91
. .
11.
Jurkovitz
CT
,
Li
S
,
Norris
KC
,
Saab
G
,
Bomback
AS
,
Whaley-Connell
AT
, et al.
Association between lack of health insurance and risk of death and ESRD: results from the kidney early evaluation program(KEEP)
.
Am J Kidney Dis
.
2013 Apr
;
61
(
4 Suppl 2
):
S24
32
. .
12.
Bieber
B
,
Qian
J
,
Anand
S
,
Yan
Y
,
Chen
N
,
Wang
M
, et al.
Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and quality of life in the china dialysis outcomes and practice patterns study
.
Nephrol Dial Transplant
.
2014 Sep
;
29
(
9
):
1770
7
. .
13.
Nee
R
,
Moon
DS
,
Jindal
RM
,
Hurst
FP
,
Yuan
CM
,
Agodoa
LY
, et al.
Impact of poverty and health care insurance on arteriovenous fistula use among incident hemodialysis patients
.
Am J Nephrol
.
2015
;
42
(
4
):
328
36
. .
14.
Glasheen
WP
,
Cordier
T
,
Gumpina
R
,
Haugh
G
,
Davis
J
,
Renda
A
.
Charlson comorbidity index: ICD-9 update and ICD-10 translation
.
Am Health Drug Benefits
.
2019 Jun–Jul
;
12
(
4
):
188
97
.
15.
Sriravindrarajah
A
,
Kotwal
SS
,
Sen
S
,
McDonald
S
,
Jardine
M
,
Cass
A
, et al.
Impact of supplemental private health insurance on dialysis and outcomes
.
Intern Med J
.
2020 May
;
50
(
5
):
542
9
. .
16.
Korean National Health
.
Insurance service [Internet]. National Health Insurance Statistical Yearbook
,
2015 [cited 2020 Oct
20]. Available from:
https://www.nhis.or.kr/menu/boardRetriveMenuSet.xx?menuId=F3321.
17.
Luo
J
,
Lee
A
,
Cohen
DE
,
Colson
C
,
Brunelli
SM
.
Vocational activity and health insurance type among patients with end-stage renal disease: association with outcomes
.
J Nephrol
.
2018 Aug
;
31
(
4
):
577
84
. .
18.
Kalbfleisch
J
,
Wolfe
R
,
Bell
S
,
Sun
R
,
Messana
J
,
Shearon
T
, et al.
Risk adjustment and the assessment of disparities in dialysis mortality outcomes
.
J Am Soc Nephrol
.
2015 Nov
;
26
(
11
):
2641
5
. .
19.
Tao
S
,
Zeng
X
,
Liu
J
,
Fu
P
.
Socioeconomic status and mortality among dialysis patients: a systematic review and meta-analysis
.
Int Urol Nephrol
.
2019 Mar
;
51
(
3
):
509
18
. .
20.
Kim
MH
,
Kim
YC
,
Lee
JP
,
Kim
H
,
Kim
DK
,
Ryu
DR
, et al.
Three-year income trends in Korean adults commencing haemodialysis: a prospective cohort
.
Nephrology
.
2018 Jul
;
23
(
7
):
625
32
. .
21.
Krishnasamy
R
,
Jegatheesan
D
,
Lawton
P
,
Gray
NA
.
Socioeconomic status and dialysis quality of care
.
Nephrology
.
2020
;
25
(
5
):
421
8
.
22.
Trivedi
AN
,
Sommers
BD
.
The affordable care act medicaid expansion and disparities in kidney disease
.
Clin J Am Soc Nephrol
.
2018 Mar 7
;
13
(
3
):
480
2
. .
23.
Choi
Y
,
Shin
J
,
Park
JT
,
Cho
KH
,
Park
EC
,
Kim
TH
.
Disparities in kidney transplantation access among Korean patients initiating dialysis: a population-based cohort study using national health insurance data (2003–2013)
.
Am J Nephrol
.
2017
;
45
(
1
):
32
9
. .
24.
Ke
C
,
Kim
SJ
,
Shah
BR
,
Bierman
AS
,
Lipscombe
LL
,
Feig
DS
, et al.
Impact of socioeconomic status on incidence of end-stage renal disease and mortality after dialysis in adults With diabetes
.
Can J Diabetes
.
2019 Oct
;
43
(
7
):
483
e4
. .
25.
Park
S
,
Park
GC
,
Park
J
,
Kim
JE
,
Yu
MY
,
Kim
K
, et al.
Disparity in accessibility to and prognosis of kidney transplantation according to economic inequality in South Korea: a widening gap after expansion of insurance coverage
.
Transplantation
.
2020 Apr 6
. .
26.
Ryu
JH
,
Kim
H
,
Kim
KH
,
Hann
HJ
,
Ahn
HS
,
Lee
S
, et al.
Improving survival rate of Korean patients initiating dialysis
.
Yonsei Med J
.
2015 May
;
56
(
3
):
666
75
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.